{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002731","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.301674+00:00","generated_at":"2026-06-07T02:12:22.368497+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Outset Medical reports Q4 rev $30.5M, FY2023 $130M (+13%), guides 2024 rev $145-153M","bullets":["Q4 revenue $30.5M; FY2023 revenue $130M, up 13% YoY.","Installed base up 34% YoY to ~5,350 Tablo systems; consumable revenue grew nearly 50% YoY.","Recurring revenue exceeded 50% of total revenue in 2023.","Borrowed $66.5M in Jan 2024; cash position ~$270M.","2024 guidance: revenue $145-153M (12-18% growth); non-GAAP gross margin low-30% for year, mid-30% in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002731","json":"https://secwatch.observer/filing/0000950170-24-002731.json","markdown":"https://secwatch.observer/filing/0000950170-24-002731.md","text":"https://secwatch.observer/filing/0000950170-24-002731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024002731/0000950170-24-002731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024002731/om-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:12:22.368497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"285a93fde888de396cdeb5ab3cf299be8e14f580","claim":"Outset Medical, Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $30.5 million. Guidance initiated.","evidence_excerpt":"year ended December 31, 2023, and provided 2024 financial guidance. Unaudited Fourth Quarter and Year End Results, and Recent Highlights • Revenue in the fourth quarter totaled $30.5 million, bringing revenue for 2023 to $130 million, a 13% increase compared to $115 million in 2022. • Period-end installed base increased 34% year-over-year to approximately 5,350","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024002731/0000950170-24-002731-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$30.5 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"489234d3e1130285f8ab8ddc27874093424056d3","claim":"Outset Medical, Inc. reported the full year 2024 results: revenue between $145 million to $153 million. Guidance initiated.","evidence_excerpt":"Outset expects 2024 revenue to be between $145 million to $153 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024002731/0000950170-24-002731-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2024"},{"label":"Revenue","value":"between $145 million to $153 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}